Skip to main content

Table 2 Patient characteristics

From: Postoperative radiotherapy for supraglottic cancer on real-world data: can we reduce dose to lymph node levels?

Characteristics

Center 1

n (%)

Center 2

n (%)

P

Gender

  

0.243

 Male

60(96.7)

57(91.9)

 

 Female

2(3.3)

5(8.1)

 

Age (y)

  

0.104

 Median; Range

58; 42–75

64; 34–79

 

Smoking index

  

0.442

 Median; Range

600; 0–2000

800; 0–2400

 

Differentiation

  

0.288

 Well

2 (3.2)

3 (6.4)

 

 Moderate

37 (59.7)

44 (71)

 

 Poor

23 (37.1)

15 (24.2)

 

Extra nodal extension

  

0.347

 Yes

13 (21.0)

9 (14.5)

 

 No

49 (79.0)

53 (85.5)

 

T stage

  

0.002*

 T1

3 (4.8)

0 (0)

 

  T2

9 (14.5)

27 (43.5)

 

  T3

40 (64.5)

32 (51.6)

 

 T4

10 (16.1)

3 (4.8)

 

N stage

  

0.004*

 N0

11 (17.7)

30 (48.4)

 

 N1

8 (12.9)

5 (8.1)

 

 N2

31 (50)

21 (33.8)

 

 N3

12 (19.4)

6 (9.7)

 

Stage (UICC 2017)

  

 < 0.001*

 II

1 (1.6)

17 (27.4)

 

 III

14 (22.6)

17 (27.4)

 

 IVA

34 (54.8)

22 (35.5)

 

 IVB

13 (21)

6 (9.7)

 

Concurrent chemotherapy

   

 Yes

27 (43.5)

7 (11.3)

 < 0.001*

 No

35 (56.5)

55 (88.7)

 

CDDP prescription

  

 < 0.001*

 100 mg/m2 every 3 weeks

25

7

 

 − 40 mg/m2 each week

2

0

 

Neck dissection

  

0.001*

 Ipsilateral

10 (16.1)

0 (0)

 

 Bilateral

52 (83.9)

62 (100)

 

Second primary cancer

13 (21)

8 (12.9)

0.231

Total

62

62

NA

  1. NA, not available. *p < 0.05